Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

Completed · Phase 4 · Has a placebo group

Conditions studied: Aneurysmal Subarachnoid Hemorrhage

In brief

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.

Key facts

Study ID

NCT02330094

Run by

Mayo Clinic

People needed

16

Starts

2014-12-01

Expected to finish

2017-09-01

Last updated by the study team

2019-09-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Have aneurysmal subarachnoid hemorrhage (aSAH) diagnosed by CT scan of the brain and/or angiogram evidence of intracranial aneurysm (CTA or digital subtraction angiogram or MRA)
• Have symptomatic headache
• Able to swallow and verbalize pain score
• No known allergy to gabapentin or fentanyl
• Numeric pain score ≥ 5
• Ability to provide written personal consent

You may not qualify if…

• Gabapentin use prior to SAH admission
• Renal failure with creatinine clearance less than 30 mL/min
• Unable to receive standard of care pain medications
• Pregnant or breastfeeding patients
• History of severe depression defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV)

Where it is running

• Mayo Clinic in Florida — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.